Open Access

Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide‑induced activation of hepatic stellate cells via suppressing inflammation

  • Authors:
    • Dayong Lou
    • Jibo Han
    • Liqin Zhou
    • Huanjie Ma
    • Jianjiang Xv
    • Junwei Shou
    • Zhixiu Xu
    • Liqin Jiang
    • Yuanyuan Qian
  • View Affiliations

  • Published online on: August 7, 2018     https://doi.org/10.3892/etm.2018.6586
  • Pages: 2909-2916
  • Copyright: © Lou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Activated hepatic stellate cells (HSCs) serve key roles in hepatic fibrosis by producing excessive extracellular matrix (ECM) components. Lipopolysaccharide (LPS) has been found to be associated with hepatic fibrogenesis through direct interactions with HSCs. Recently, the fibroblast growth factor receptor 1 (FGFR1) signalling system was identified as a key player in the process of liver fibrosis. In the present study it was evaluated whether FGFR1 mediated LPS‑induced HSCs activation. In cultured cells, FGFR1 was inhibited by either siRNA silencing or by a small‑molecule inhibitor in LPS‑stimulated HSCs. The blockade of FGFR1 decreased LPS‑induced nuclear factor‑κB (NF‑κB) activation, inflammatory cytokine release, fibrosis, and cell proliferation in HSCs. It was further indicated that LPS triggered FGFR1 phosphorylation via TLR4/c‑Src. These findings confirmed the detrimental effect of FGFR1 activation in the pathogenesis of LPS‑related HSC activation and revealed that FGFR1 may be an ideal therapeutic target for LPS‑induced liver fibrosis.
View Figures
View References

Related Articles

Journal Cover

October-2018
Volume 16 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lou D, Han J, Zhou L, Ma H, Xv J, Shou J, Xu Z, Jiang L and Qian Y: Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide‑induced activation of hepatic stellate cells via suppressing inflammation. Exp Ther Med 16: 2909-2916, 2018.
APA
Lou, D., Han, J., Zhou, L., Ma, H., Xv, J., Shou, J. ... Qian, Y. (2018). Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide‑induced activation of hepatic stellate cells via suppressing inflammation. Experimental and Therapeutic Medicine, 16, 2909-2916. https://doi.org/10.3892/etm.2018.6586
MLA
Lou, D., Han, J., Zhou, L., Ma, H., Xv, J., Shou, J., Xu, Z., Jiang, L., Qian, Y."Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide‑induced activation of hepatic stellate cells via suppressing inflammation". Experimental and Therapeutic Medicine 16.4 (2018): 2909-2916.
Chicago
Lou, D., Han, J., Zhou, L., Ma, H., Xv, J., Shou, J., Xu, Z., Jiang, L., Qian, Y."Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide‑induced activation of hepatic stellate cells via suppressing inflammation". Experimental and Therapeutic Medicine 16, no. 4 (2018): 2909-2916. https://doi.org/10.3892/etm.2018.6586